William Kofi Anyan

TL;DR: This report provides the first evidence of in vitroSchistosomicidal potency of R. vomitoria with the stem bark being moderately, but relatively, more active and selective against schistosome parasites, and suggests the presence of promising medicinal constituent(s).

TL;DR: Active extracts may be potential sources for developing new chemotherapy against these infections and induced varying morphological changes in Leishmania parasites such as multiple nuclei and/or kinetoplast, incomplete flagella division, or nuclear fragmentation.

TL;DR: Three novel tetracyclic iridoids, molucidin, ML-2-3, and ML-F52, from the CHCl3 fraction of M. lucida leaves, which possess activity against the GUTat 3.1 strain of T. Brucei brucei, may be promising lead compounds for the development of new chemotherapies for African trypanosomal infections in humans and animals.

TL;DR: Two of the three compounds, molucidin and ML-F52, are found to have anti-Leishmania activity against both strains, suggesting that compounds might inhibit cytokinesis in Leishmania parasites.

TL;DR: This study could provide baseline information which can be used to develop plant-based alternative commercial drugs against S. mansoni in a time and concentration-dependent manner and demonstrate the highest cercaricidal and alduticidal activities in vitro and in vivo.